Page last updated: 2024-10-30

memantine and Aging

memantine has been researched along with Aging in 33 studies

Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.

Research Excerpts

ExcerptRelevanceReference
" Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium."4.79Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. ( Camicioli, R; Ganzini, L; Young, BK, 1997)
"Memantine is a non-competitive low-affinity antagonist of the NMDA receptor with a t(1/2) of 70 h."2.49Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. ( Eap, CB; Noetzli, M, 2013)
"Memantine (MEM) has been indicated to dramatically increase hippocampal neurogenesis by promoting the proliferation of RGLs."1.42Protection of Radial Glial-Like Cells in the Hippocampus of APP/PS1 Mice: a Novel Mechanism of Memantine in the Treatment of Alzheimer's Disease. ( Bao, X; Cai, Y; Chen, J; Fan, X; Huang, J; Huang, W; Sun, D; Xu, H; Zhao, J, 2015)
"Memantine is a low-affinity voltage-dependent noncompetitive antagonist at glutamatergic NMDA receptors."1.42Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil. ( Akishita, M; Ogawa, S; Ota, H; Ouchi, Y, 2015)
"Memantine pretreatment was able to prevent the cognitive impairment caused by SD in both age groups, while it had no negative effect on CTL animals."1.40Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus. ( Blin, O; Bordet, R; Canovi, M; Cella, M; Estrada, C; Fernández-Villalba, E; Gobbi, M; Gonzalez-Cuello, A; Guiso, G; Herrero, MT; Lamberty, Y; Lopez, D; Pifferi, F; Richardson, JC; Ros, CM; Tarragon, E, 2014)
"Currently there is no treatment for juvenile Batten disease, a fatal childhood neurodegenerative disorder caused by mutations in the CLN3 gene."1.38Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease. ( Cooper, JD; Kovács, AD; Pearce, DA; Ramji, S; Saje, A; Wong, A, 2012)
"Memantine treatment also was associated with a decline in the levels of total tau and hyperphosphorylated tau."1.36Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. ( Albrecht, M; Banerjee, P; Billings, LM; Green, KN; Gupta, S; Kitazawa, M; LaFerla, FM; Martinez-Coria, H; Parsons, CG; Rammes, G, 2010)
"Treatment with memantine decreased Glu/Cr (creatine) ratio in the left hippocampal region."1.35Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study. ( de Leon, MJ; De Santi, S; Glodzik, L; Gonen, O; King, KG; Liu, S, 2008)
"Memantine-treated rats showed normal recognition memory while the saline group showed long-term recognition memory deficits."1.34Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. ( Budni, P; Constantino, L; Dal-Pizzol, F; Dornelles, A; Garcia, VA; Martins de Lima, MN; Pietá Dias, C; Presti-Torres, J; Rewsaat Guimarães, M; Schröder, N; Siciliani Scalco, F, 2007)
"Other causes of dementia have overlapping presentations, but with important differences."1.32Does this patient have Alzheimer disease? Diagnosing and treating dementia. ( Messinger-Rapport, BJ, 2003)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (6.06)18.2507
2000's12 (36.36)29.6817
2010's19 (57.58)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J6
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q4
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X4
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J4
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X4
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z3
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X6
Xu, N1
Wang, R1
Liu, S2
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y6
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y7
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H3
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J7
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y7
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Wang, L3
Hu, T1
Wang, F1
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y4
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J3
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z3
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y2
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L3
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X3
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z2
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J3
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J1
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J3
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L1
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Rahman, A1
Lamberty, Y2
Schenker, E1
Cella, M2
Languille, S1
Bordet, R2
Richardson, J1
Pifferi, F2
Aujard, F1
Noetzli, M1
Eap, CB1
Karolczak, D1
Sawicka, E1
Dorszewska, J1
Radel, A1
Bodnar, M1
Błaszczyk, A1
Jagielska, J1
Marszałek, A1
Tarragon, E1
Lopez, D1
Estrada, C1
Gonzalez-Cuello, A1
Ros, CM1
Canovi, M1
Guiso, G1
Gobbi, M1
Fernández-Villalba, E1
Blin, O1
Richardson, JC1
Herrero, MT1
Sun, D1
Bao, X1
Zhao, J1
Huang, W1
Fan, X1
O'Connor, RM1
Moloney, RD1
Glennon, J1
Vlachou, S1
Cryan, JF1
Ota, H1
Ogawa, S1
Ouchi, Y1
Akishita, M1
Pinho, J1
Vale, R1
Batalha, VL1
Costenla, AR1
Dias, R1
Rombo, D1
Sebastião, AM1
de Mendonça, A1
Diógenes, MJ1
Graham, WV1
Bonito-Oliva, A1
Sakmar, TP1
Yamada, J1
Ohgomori, T1
Jinno, S1
Burke, SN1
Maurer, AP1
Navratilova, Z1
Barnes, CA1
Doody, RS1
Namba, T1
Maekawa, M1
Yuasa, S1
Kohsaka, S1
Uchino, S1
El-Moursy, SA1
Shawky, HM1
Abdel Wahab, Z1
Rashed, L1
Martinez-Coria, H1
Green, KN1
Billings, LM1
Kitazawa, M1
Albrecht, M1
Rammes, G1
Parsons, CG2
Gupta, S1
Banerjee, P2
LaFerla, FM1
Nyakas, C1
Granic, I1
Halmy, LG1
Luiten, PG1
Vandesquille, M1
Krazem, A1
Louis, C1
Lestage, P1
Béracochéa, D2
Terry, AV1
Callahan, PM1
Hall, B1
Webster, SJ1
Stefanacci, RG1
Whitney, KN1
Wenger, GR1
Kovács, AD1
Saje, A1
Wong, A1
Ramji, S1
Cooper, JD1
Pearce, DA1
Schneider, JS1
Pioli, EY1
Jianzhong, Y1
Li, Q1
Bezard, E1
Schuettauf, F1
Quinto, K1
Naskar, R1
Zurakowski, D1
Messinger-Rapport, BJ1
Richartz, E1
Schott, KJ1
Wormstall, H1
Royall, DR1
Morris, JC1
Pietá Dias, C1
Martins de Lima, MN1
Presti-Torres, J1
Dornelles, A1
Garcia, VA1
Siciliani Scalco, F1
Rewsaat Guimarães, M1
Constantino, L1
Budni, P1
Dal-Pizzol, F1
Schröder, N1
Boucard, A1
Trocme-Thibierge, C1
Morain, P1
Glodzik, L1
King, KG1
Gonen, O1
De Santi, S1
de Leon, MJ1
Bresink, I1
Danysz, W1
Tiedtke, P1
Mutschler, E1
Young, BK1
Camicioli, R1
Ganzini, L1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment[NCT01876823]Phase 2/Phase 360 participants (Actual)Interventional2006-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in 24-item HAMD

Change in 24-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to Week 48: HAMD measures depression severity based on a series of 24 items items. The range of HAMD total score is 0-74; 0 indicates no depressive symptoms and a maximum HAMD score is a 74, where the greater the score indicates more significant psychopathology. In this study, moderate to severe depression is considered a HAMD-24 greater than 14. (NCT01876823)
Timeframe: Baseline, Week 48

Interventionscores on a scale (Mean)
Es-citalopram and Memantine Treatment-15.2

Change in Selective Reminding Test - Delayed Recall (SRT-DR)

Change in Selective Reminding Test-Delayed Recall scores from baseline to Week 48: SRT Delay is administered 15 minutes after the immediate recall portion. Patients are asked to remember as many of the words as they can from the 6 trials. Maximum raw score is a 12 for free recall. If a patient is unable to recall a word, they are given a chance to recognize it among three incorrect word choices. Maximum raw score for recognition is 12. The greater the score on the delayed recall portion, the better the patient does on the assessment. (NCT01876823)
Timeframe: Baseline, Week 48

Interventionunits on a scale (Mean)
Es-citalopram and Memantine Treatment1.2

Change in Selective Reminding Test - Total Immediate Recall (SRT-IR)

Change in Selective Reminding Test-Total Immediate Recall (SRT-IR) scores from baseline to Week 48: Measures word recall (maximum 12 words per trial, across 6 trials). Maximum total recall score across 6 trials is 72; minimum recall is 0 across 6 trials. The higher the raw score, the better the patient did at recalling the target words. The unit of measure is the raw score, or the sum of the number of words recalled across all 6 trials. (NCT01876823)
Timeframe: baseline, 48 weeks

Interventionunits on a scale (Mean)
Es-citalopram and Memantine Treatment7.5

Change in Trails A

Change in Trails A scores from baseline to Week 48: Measures attention and executive function. It asks patients to connect numbers from 1-25 in numerical order as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48

Interventionseconds (Mean)
Es-citalopram and Memantine Treatment1.9

Change in Trails B

Change from baseline to Week 48 on Trails B: Measures attention and executive function. It asks patients to connect numbers and letters in numerical to alphabetical order from (1-13 and A-L) as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers and letters, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48

Interventionseconds (Mean)
Es-citalopram and Memantine Treatment-36.3

Change in Wechsler Memory Scale-III (WMS-III)

Change in Wechsler Memory Scale-III scores from baseline to Week 48: The WMS-III Visual Reproduction sub-test was used to measure visual working memory and delayed memory. Patients were shown pictures of four drawings and were asked to reproduce them from memory immediately after seeing them, and 25 minutes after seeing them. The four scores are summed and the greater the total raw score, the better the patient did on the assessment. The maximum raw score for this test is a 41 on both the immediate and delayed portions (the overall range is 0-82 points). The change score is calculated using the total scores of both the immediate and delayed portions. (NCT01876823)
Timeframe: Baseline, Week 48

Interventionunits on a scale (Mean)
Es-citalopram and Memantine Treatment9.9

Conversion to Dementia Using Clinical Dementia Rating (CDR)

The CDR is a numeric rating scale that is used to quantify the severity of one's cognitive function. The scale goes from 0=normal; 0.5=mild cognitive impairment; 1 to 3=mild to moderate/severe dementia. CDR was used a dichotomous outcome measure (no=0; yes=1). (NCT01876823)
Timeframe: Baseline, Week 48

Interventionparticipants (Number)
Es-citalopram and Memantine Treatment1

Change in Clinical Global Impression - Cognitive Change

The CGI Cognitive Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses from the entire group were calculated. Mean at final visit and baseline is reported below. (NCT01876823)
Timeframe: Baseline, Week 48

Interventionunits on a scale (Mean)
CGI-Cognitive Change (Baseline)Clinical Global Impression-Cogntive Change (WK 48)
Es-citalopram and Memantine Treatment3.62.7

Change in Clinical Global Impression - Depression Change

The CGI Depression Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses were calculated for the entire group. Mean at final visit has been reported below. Higher mean at baseline indicates a decrease in depression scores. (NCT01876823)
Timeframe: Baseline, Week 48

Interventionunits on a scale (Mean)
Cognitive Global Impression at BaselineCognitive Global Impression at Final Visit (WK 48)
Es-citalopram and Memantine Treatment4.12.1

Change in Treatment Emergent Side Effects (TESS)

"Somatic side effect rating scale which includes 26 common somatic side effects associated with previous medication clinical trials; rated by the study physician. Factors were dichotomized to yes or no responses on this scale, which equated to the symptom being either present or not present. Yes and no responses were given a value of 0 (no) or 1 (yes). Responses from the entire group were calculated and the mean at baseline and the last visit is reported below." (NCT01876823)
Timeframe: Baseline, Week 48

Interventionunits on a scale (Mean)
Treatment Emergent Side Effects (Baseline)Treatment Emergent Side Effects (WK 48)
Es-citalopram and Memantine Treatment6.63.2

Reviews

9 reviews available for memantine and Aging

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
    Clinical pharmacokinetics, 2013, Volume: 52, Issue:4

    Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; G

2013
Update on Alzheimer's Disease Therapy and Prevention Strategies.
    Annual review of medicine, 2017, 01-14, Volume: 68

    Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Excitatory Amin

2017
Cholinesterase inhibitors and memantine: best practices.
    CNS spectrums, 2008, Volume: 13, Issue:10 Suppl 1

    Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Memantine; Practice Patterns, Physician

2008
Alzheimer's disease and age-related memory decline (preclinical).
    Pharmacology, biochemistry, and behavior, 2011, Volume: 99, Issue:2

    Topics: Aging; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Histamine H3 A

2011
The costs of Alzheimer's disease and the value of effective therapies.
    The American journal of managed care, 2011, Volume: 17 Suppl 13

    Topics: Age Factors; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Ga

2011
[Psychotropic drug treatment in dementia disorders].
    Deutsche medizinische Wochenschrift (1946), 2004, Jun-18, Volume: 129, Issue:25-26

    Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents; Cholinesterase Inhibitors; Dementia; Dose-Res

2004
Mild cognitive impairment and preclinical Alzheimer's disease.
    Geriatrics, 2005, Volume: Suppl

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antiparkinson Agents;

2005
Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.
    Drugs & aging, 1997, Volume: 10, Issue:5

    Topics: Aging; Akathisia, Drug-Induced; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Cholinergic

1997

Trials

1 trial available for memantine and Aging

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016

Other Studies

24 other studies available for memantine and Aging

ArticleYear
Effects of acute administration of donepezil or memantine on sleep-deprivation-induced spatial memory deficit in young and aged non-human primate grey mouse lemurs (Microcebus murinus).
    PloS one, 2017, Volume: 12, Issue:9

    Topics: Aging; Alzheimer Disease; Animals; Cheirogaleidae; Disease Models, Animal; Donepezil; Indans; Male;

2017
Memantine - neuroprotective drug in aging brain.
    Polish journal of pathology : official journal of the Polish Society of Pathologists, 2013, Volume: 64, Issue:3

    Topics: Aging; Animals; Apoptosis; Brain; Caspase 3; Caspase 9; Enzyme Activation; Female; Immunohistochemis

2013
Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus.
    Neuropharmacology, 2014, Volume: 85

    Topics: Aging; Animals; Female; Maze Learning; Memantine; Memory Disorders; Memory, Short-Term; Neuropsychol

2014
Protection of Radial Glial-Like Cells in the Hippocampus of APP/PS1 Mice: a Novel Mechanism of Memantine in the Treatment of Alzheimer's Disease.
    Molecular neurobiology, 2015, Volume: 52, Issue:1

    Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Apoptosis; Bromodeoxyuridine; Cel

2015
Enhancing glutamatergic transmission during adolescence reverses early-life stress-induced deficits in the rewarding effects of cocaine in rats.
    Neuropharmacology, 2015, Volume: 99

    Topics: Administration, Intravenous; Aging; Amino Acid Transport System X-AG; Animals; Cocaine; Cocaine-Rela

2015
Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil.
    Experimental gerontology, 2015, Volume: 72

    Topics: Aging; Alzheimer Disease; Animals; beta-Galactosidase; Cholinesterase Inhibitors; Cognition; Disease

2015
Enhanced LTP in aged rats: Detrimental or compensatory?
    Neuropharmacology, 2017, 03-01, Volume: 114

    Topics: Aging; Animals; Excitatory Postsynaptic Potentials; Hippocampus; Long-Term Potentiation; Male; Maze

2017
Alterations in expression of Cat-315 epitope of perineuronal nets during normal ageing, and its modulation by an open-channel NMDA receptor blocker, memantine.
    The Journal of comparative neurology, 2017, Jun-15, Volume: 525, Issue:9

    Topics: Aging; Animals; Antibodies, Monoclonal; Brain; CD57 Antigens; Cell Count; Epitopes; Excitatory Amino

2017
Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats.
    Behavioral neuroscience, 2008, Volume: 122, Issue:3

    Topics: Age Factors; Aging; Analysis of Variance; Animals; Behavior, Animal; Conditioning, Psychological; Di

2008
The Alzheimer's disease drug memantine increases the number of radial glia-like progenitor cells in adult hippocampus.
    Glia, 2009, Aug-01, Volume: 57, Issue:10

    Topics: Aging; Alzheimer Disease; Animals; Biomarkers; Bromodeoxyuridine; Cell Differentiation; Cell Divisio

2009
The effect of memantine and levodopa/carbidopa on the responses of phrenic nerve-diaphragm preparations from aged rats.
    Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:11

    Topics: Aging; Animals; Carbidopa; Diaphragm; Electric Stimulation; Gallamine Triethiodide; Gene Expression

2009
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice.
    The American journal of pathology, 2010, Volume: 176, Issue:2

    Topics: Age Factors; Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antiparkinson Agents; Cogniti

2010
The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine.
    Behavioural brain research, 2011, Aug-10, Volume: 221, Issue:2

    Topics: Aging; Amyloid beta-Peptides; Animals; Attention; Avoidance Learning; Cholinergic Fibers; Dementia;

2011
S 18986 reverses spatial working memory impairments in aged mice: comparison with memantine.
    Psychopharmacology, 2011, Volume: 215, Issue:4

    Topics: Aging; Alzheimer Disease; Animals; Behavior, Animal; Benzothiadiazines; Excitatory Amino Acid Antago

2011
Working memory in the aged Ts65Dn mouse, a model for Down syndrome.
    Behavioural brain research, 2012, Jun-15, Volume: 232, Issue:1

    Topics: Aging; Animals; Antidepressive Agents; Central Nervous System Stimulants; Cognition; Conditioning, O

2012
Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease.
    Neuropharmacology, 2012, Volume: 63, Issue:5

    Topics: Aging; Animals; Cerebral Cortex; Disease Models, Animal; Disease Progression; Dose-Response Relation

2012
Effects of memantine and galantamine on cognitive performance in aged rhesus macaques.
    Neurobiology of aging, 2013, Volume: 34, Issue:4

    Topics: Aging; Animals; Association Learning; Cognition; Galantamine; Macaca mulatta; Male; Memantine; Treat

2013
Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model.
    Vision research, 2002, Volume: 42, Issue:20

    Topics: Aging; Analysis of Variance; Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival;

2002
Does this patient have Alzheimer disease? Diagnosing and treating dementia.
    Cleveland Clinic journal of medicine, 2003, Volume: 70, Issue:9

    Topics: Activities of Daily Living; Aged; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Dis

2003
The emperor has no clothes: dementia treatment on the eve of the aging era.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:1

    Topics: Aged; Aging; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Dopamine Agents; Evidenc

2005
Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats.
    Neuroscience, 2007, Jun-08, Volume: 146, Issue:4

    Topics: Aging; Animals; Behavior, Animal; Excitatory Amino Acid Antagonists; Exploratory Behavior; Male; Mem

2007
Improvement of contextual memory by S 24795 in aged mice: comparison with memantine.
    Psychopharmacology, 2008, Volume: 196, Issue:4

    Topics: Aging; alpha7 Nicotinic Acetylcholine Receptor; Animals; Discrimination Learning; Male; Memantine; M

2008
Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, May-15, Volume: 32, Issue:4

    Topics: Adult; Aged; Aging; Alzheimer Disease; Cognition Disorders; Excitatory Amino Acid Antagonists; Femal

2008
Chronic treatment with the uncompetitive NMDA receptor antagonist memantine influences the polyamine and glycine binding sites of the NMDA receptor complex in aged rats.
    Journal of neural transmission. Parkinson's disease and dementia section, 1995, Volume: 10, Issue:1

    Topics: Aging; Animals; Binding Sites; Cerebral Cortex; Dizocilpine Maleate; Dopamine Agents; Glycine; Male;

1995